J & J gives Actelion freedom to grow

19 June 2017 | updated 19 June 2017

Allschwil BL – Actelion will continue to grow within the Johnson & Johnson group, new boss Jane Griffiths said in an interview. The company has largely retained organisational independence.

Jane Griffiths intends to safeguard Actelion’s corporate culture. “Part of my role will be to help Actelion’s employees orientate themselves in their new environment,” said the new global head of Actelion in an interview with the newspaper “NZZ am Sonntag”. She added that she will try to “maintain the biotech feeling”.

The company’s employees should not worry about redundancies. “On the contrary,” said Griffiths. “We want to increase our importance in Switzerland.” Actelion will remain its “own, even if not fully independent, organisation” – particularly because the company’s revised therapy area will be new to Johnson & Johnson’s pharmaceutical branch Janssen.

Following the departure of some of its scientists to Idorsia, the new research firm created by Actelion’s founders Jean-Paul und Martine Clozel, Actelion is now looking for new projects globally. “We need more ‘babies’,” said Griffiths.

Johnson & Johnson acquired Actelion for USD 30 billion, and owns a stake in the newly listed Actelion spin-off Idorsia. British Jane Griffiths was previously Janssen group chairperson for Europe, Middle East and Africa.